Porous silicon-poly(ε-caprolactone) film composites: evaluation of drug release and degradation behavior

Nelli K. Bodiford, Steven J.P. McInnes, Nicolas H. Voelcker, Jeffery L. Coffer

Research output: Contribution to journalArticleResearchpeer-review

Abstract

This work focuses on an evaluation of novel composites of porous silicon (pSi) with the biocompatible polymer ε-polycaprolactone (PCL) for drug delivery and tissue engineering applications. The degradation behavior of the composites in terms of their morphology along with the effect of pSi on polymer degradation was monitored. PSi particles loaded with the drug camptothecin (CPT) were physically embedded into PCL films formed from electrospun PCL fiber sheets. PSi/PCL composites revealed a release profile of CPT (monitored via fluorescence spectroscopy) in accordance with the Higuchi release model, with significantly lower burst release percentage compared to pSi microparticles alone. Degradation studies of the composites, using gravimetric analysis, differential scanning calorimetry (DSC), and field emission scanning electron microscopy (FESEM), carried out in phosphate-buffered saline (PBS) under simulated physiological conditions, indicated a modest mass loss (15%) over 5 weeks due to pSi dissolution and minor polymer hydrolysis. DSC results showed that, relative to PCL-only controls, pSi suppressed crystallization of the polymer film during PBS exposure. This suppression affects the evolution of surface morphology during this exposure that, in turn, influences the degradation behavior of the polymer. The implications of the above properties of these composites as a possible therapeutic device are discussed.

Original languageEnglish
Article number71
Number of pages9
JournalBiomedical Microdevices
Volume20
Issue number3
DOIs
Publication statusPublished - 1 Sep 2018

Keywords

  • Camptothecin
  • Drug delivery
  • Polycaprolactone
  • Porous silicon
  • Tissue engineering

Cite this

@article{d05ea70f679442eaa78cb206cc822e9e,
title = "Porous silicon-poly(ε-caprolactone) film composites: evaluation of drug release and degradation behavior",
abstract = "This work focuses on an evaluation of novel composites of porous silicon (pSi) with the biocompatible polymer ε-polycaprolactone (PCL) for drug delivery and tissue engineering applications. The degradation behavior of the composites in terms of their morphology along with the effect of pSi on polymer degradation was monitored. PSi particles loaded with the drug camptothecin (CPT) were physically embedded into PCL films formed from electrospun PCL fiber sheets. PSi/PCL composites revealed a release profile of CPT (monitored via fluorescence spectroscopy) in accordance with the Higuchi release model, with significantly lower burst release percentage compared to pSi microparticles alone. Degradation studies of the composites, using gravimetric analysis, differential scanning calorimetry (DSC), and field emission scanning electron microscopy (FESEM), carried out in phosphate-buffered saline (PBS) under simulated physiological conditions, indicated a modest mass loss (15{\%}) over 5 weeks due to pSi dissolution and minor polymer hydrolysis. DSC results showed that, relative to PCL-only controls, pSi suppressed crystallization of the polymer film during PBS exposure. This suppression affects the evolution of surface morphology during this exposure that, in turn, influences the degradation behavior of the polymer. The implications of the above properties of these composites as a possible therapeutic device are discussed.",
keywords = "Camptothecin, Drug delivery, Polycaprolactone, Porous silicon, Tissue engineering",
author = "Bodiford, {Nelli K.} and McInnes, {Steven J.P.} and Voelcker, {Nicolas H.} and Coffer, {Jeffery L.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1007/s10544-018-0313-5",
language = "English",
volume = "20",
journal = "Biomedical Microdevices",
issn = "1387-2176",
publisher = "Springer-Verlag London Ltd.",
number = "3",

}

Porous silicon-poly(ε-caprolactone) film composites : evaluation of drug release and degradation behavior. / Bodiford, Nelli K.; McInnes, Steven J.P.; Voelcker, Nicolas H.; Coffer, Jeffery L.

In: Biomedical Microdevices, Vol. 20, No. 3, 71, 01.09.2018.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Porous silicon-poly(ε-caprolactone) film composites

T2 - evaluation of drug release and degradation behavior

AU - Bodiford, Nelli K.

AU - McInnes, Steven J.P.

AU - Voelcker, Nicolas H.

AU - Coffer, Jeffery L.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - This work focuses on an evaluation of novel composites of porous silicon (pSi) with the biocompatible polymer ε-polycaprolactone (PCL) for drug delivery and tissue engineering applications. The degradation behavior of the composites in terms of their morphology along with the effect of pSi on polymer degradation was monitored. PSi particles loaded with the drug camptothecin (CPT) were physically embedded into PCL films formed from electrospun PCL fiber sheets. PSi/PCL composites revealed a release profile of CPT (monitored via fluorescence spectroscopy) in accordance with the Higuchi release model, with significantly lower burst release percentage compared to pSi microparticles alone. Degradation studies of the composites, using gravimetric analysis, differential scanning calorimetry (DSC), and field emission scanning electron microscopy (FESEM), carried out in phosphate-buffered saline (PBS) under simulated physiological conditions, indicated a modest mass loss (15%) over 5 weeks due to pSi dissolution and minor polymer hydrolysis. DSC results showed that, relative to PCL-only controls, pSi suppressed crystallization of the polymer film during PBS exposure. This suppression affects the evolution of surface morphology during this exposure that, in turn, influences the degradation behavior of the polymer. The implications of the above properties of these composites as a possible therapeutic device are discussed.

AB - This work focuses on an evaluation of novel composites of porous silicon (pSi) with the biocompatible polymer ε-polycaprolactone (PCL) for drug delivery and tissue engineering applications. The degradation behavior of the composites in terms of their morphology along with the effect of pSi on polymer degradation was monitored. PSi particles loaded with the drug camptothecin (CPT) were physically embedded into PCL films formed from electrospun PCL fiber sheets. PSi/PCL composites revealed a release profile of CPT (monitored via fluorescence spectroscopy) in accordance with the Higuchi release model, with significantly lower burst release percentage compared to pSi microparticles alone. Degradation studies of the composites, using gravimetric analysis, differential scanning calorimetry (DSC), and field emission scanning electron microscopy (FESEM), carried out in phosphate-buffered saline (PBS) under simulated physiological conditions, indicated a modest mass loss (15%) over 5 weeks due to pSi dissolution and minor polymer hydrolysis. DSC results showed that, relative to PCL-only controls, pSi suppressed crystallization of the polymer film during PBS exposure. This suppression affects the evolution of surface morphology during this exposure that, in turn, influences the degradation behavior of the polymer. The implications of the above properties of these composites as a possible therapeutic device are discussed.

KW - Camptothecin

KW - Drug delivery

KW - Polycaprolactone

KW - Porous silicon

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=85051510175&partnerID=8YFLogxK

U2 - 10.1007/s10544-018-0313-5

DO - 10.1007/s10544-018-0313-5

M3 - Article

VL - 20

JO - Biomedical Microdevices

JF - Biomedical Microdevices

SN - 1387-2176

IS - 3

M1 - 71

ER -